{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:36:25Z","timestamp":1770899785432,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,11]]},"DOI":"10.7759\/cureus.14414","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T13:48:17Z","timestamp":1618148897000},"source":"Crossref","is-referenced-by-count":5,"title":["Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma"],"prefix":"10.7759","author":[{"given":"Hamid-Reza","family":"Moein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafic","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray N","family":"Ehrinpreis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2015.06.005","article-title":"Ipilimumab-induced colitis: a new challenge for gastroenterologists [Article in Spanish]]","volume":"39","author":"Mesonero F","year":"2016","unstructured":"Mesonero F, L\u00f3pez-Sanrom\u00e1n A, Madariaga A, Soria A. Ipilimumab-induced colitis: a new challenge for gastroenterologists [Article in Spanish]]. Gastroenterol Hepatol. 2016, 39:233-8. 10.1016\/j.gastrohep.2015.06.005","journal-title":"Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat S","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al.. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016, 27:559-74. 10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint inhibitor-induced colitis","volume":"115","author":"Bellaguarda E","year":"2020","unstructured":"Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol. 2020, 115:202-10. 10.14309\/ajg.0000000000000497","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-019-03268-4","article-title":"Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike\u2014report of new cases and review of the literature","volume":"34","author":"Ca\u00f1ete F","year":"2019","unstructured":"Ca\u00f1ete F, Ma\u00f1osa M, Lobat\u00f3n T, et al.. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike\u2014report of new cases and review of the literature. Int J Colorectal Dis. 2019, 34:861-5. 10.1007\/s00384-019-03268-4","journal-title":"Int J Colorectal Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung VTF","year":"2020","unstructured":"Cheung VTF, Gupta T, Olsson-Brown A, et al.. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. Br J Cancer. 2020, 123:207-15. 10.1038\/s41416-020-0882-y","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang Y","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al.. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018, 6:37. 10.1186\/s40425-018-0346-6","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac C","year":"2017","unstructured":"Coutzac C, Adam J, Soularue E, et al.. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017, 11:1238-46. 10.1093\/ecco-jcc\/jjx081","journal-title":"J Crohns Colitis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih H","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018, 6:95. 10.1186\/s40425-018-0411-1","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang Y","year":"2018","unstructured":"Wang Y, Wiesnoski DH, Helmink BA, et al.. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018, 24:1804-8. 10.1038\/s41591-018-0238-9","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031717","article-title":"Ustekinumab for refractory colitis associated with immune checkpoint inhibitors","volume":"384","author":"Thomas AS","year":"2021","unstructured":"Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021, 384:581-3. 10.1056\/NEJMc2031717","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2002527","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani K","year":"2020","unstructured":"Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020, 382:2374-5. 10.1056\/NEJMc2002527","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/55349-ipilimumab-and-nivolumab-induced-colitis-in-a-patient-with-recurrent-metastatic-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:10Z","timestamp":1707506830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/55349-ipilimumab-and-nivolumab-induced-colitis-in-a-patient-with-recurrent-metastatic-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.14414","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,11]]}}}